zenotech

CIN: L27100TG1989PLC010122
ZENOTECH LABORATORIES LIMITED
Registered Office & Factory:
Survey No.250 -252
Turkapally Village, Genome Valley Road,
Shamirpet Mandal,
Medchal-Malkajgiri Dist.,
Turkapalliyadaram,
Hyderabad - 500 101 Telangana, India.
Tel: +91 90320 44584/ 585
Email: info@zenotech.co.in
www.zenotechlab.com

Date: July 28, 2026

BSE Limited
Corporate Relationship Dept.,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 532039

Sub: Zenotech Laboratories Limited - Outcome of the Board Meeting held today, i.e., July 28, 2026

Further to the communication dated July 13, 2026, pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") this is to inform that the Meeting of the Board of Directors of the Company ("Board") was held today, i.e., July 28, 2026, which commenced at 11:30 A.M. and concluded at 2:30 P.M., IST. The Board has, *inter-alia:*

1. **Approved Unaudited Standalone Financial Results**

   The Unaudited Standalone Financial Results for the quarter ended June 30, 2026, as approved pursuant to Regulation 33 of the Listing Regulations, along with the Limited Review Report of the Statutory Auditors, are annexed herewith as **Annexure A**.

2. **Approved convening 37th Annual General Meeting**

   The 37th Annual General Meeting ("AGM") of the Company will be held on Friday, September 25, 2026, at 10:30 A.M. IST through Videoconferencing. The Notice of the AGM and the Annual Report will be released in due course.

   Shareholders are requested to get their information updated with the depositories (for shares held in demat) or with the Company's RTA (for shares held in physical form), so that Notice of the AGM and the Annual Report can be received by email.

For **Zenotech Laboratories Limited**
ABDUL GAFOOR MOHAMMAD

Digitally signed by ABDUL GAFOOR MOHAMMAD
DN: c=IN, o=Personal, title=8560, pseudonym=rlkbz7h5t34msvwaq68dfypgocje9i0x, 2.5.4.20=cbc6f397a0a7f438933adbedabbaa081b2fdf7ff5c01f1914af49f14d3b7f8fe, postalCode=500089, st=Andhra Pradesh, serialNumber=2bd0f97474015a367f30a376d50d0ff4cb01774828a4d39bfd30165c3498d605, cn=ABDUL GAFOOR MOHAMMAD
Date: 2026.07.28 14:39:14 +05'30'

(Abdul Gafoor Mohammad)
Company Secretary & Compliance Officer
ICSI Membership No. A22331

Encl: as above

G S K A & Co.
Chartered Accountants

4th floor, Red building,
Above Shinhan Bank,
Boat Club Road,
Pune – 411 001

Independent Auditor's Review Report On the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

Review Report To
The Board of Directors
Zenotech Laboratories Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Zenotech Laboratories Limited (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed , or that it contains any material misstatement.

For **G S K A & Co.**
Chartered Accountants
ICAI Firm Registration Number: 147093W

per **Ganesh Gaikwad**
Partner
Membership Number: 136512
UDIN: 26136512WXBCEL5996
Place of signature: Pune
Date: July 28, 2026

G S K A & CO.
FRN
147093W
PUNE
Chartered Accountants

ZENOTECH LABORATORIES LIMITED
CIN: L27100TG1989PLC010122
Survey No.250-252, Turkapally Village, Genome Valley Road, Shameerpet Mandal,
Medchal-Malkajgiri District, Hyderabad - 500101, Telangna
Phone:+91 90320 44584/585/586 Website: www.zenotechlab.com
Statement of unaudited standalone financial results for the quarter ended June 30, 2026

(Rs in lakhs, except earnings per share)

Sl. No.	Particulars	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited (Refer Note 6)	Unaudited	Audited
I	Revenue from operations	959.64	886.50	863.91	3,956.20
II	Other operating income	101 58	101.56	100.41	405.16
III	Other Income	43 57	59.65	58.84	230.90
IV	**Total Income (I+II+III)**	**1,104.79**	**1,047.71**	**1,023.16**	**4,592.26**
V	**Expenses**				
	a). Cost of materials consumed	-	-	-	-
	b). Purchase of Stock-in-Trade	-	-	-	-
	c). Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	d). Employee benefit expenses	491.63	416.63	353.56	1,552 79
	e). Depreciation and amortization expense	190.23	175.80	177.37	711 34
	f). Other expenses	483.00	554.24	364.55	1,889.72
	Total expenses	**1,164.86**	**1,146.67**	**895.48**	**4,153.85**
VI	**Profit/(Loss) before exceptional items and tax (IV-V)**	**(60.07)**	**(98.96)**	**127.68**	**438.41**
VII	Exceptional items	-	5.41	-	(19.51)
VIII	Profit/(Loss) before tax (VI-VII)	(60 07)	(93.55)	127.68	418.90
IX	Tax expense				
	a). Current tax	-	-	22.21	-
	b). Prior period tax	-	239.42	-	48 93
	c). Deferred tax	(14.52)	(17.89)	6.52	477.18
	Total tax expense (IX)	(14.52)	221.53	28.72	526.11
X	Profit/(Loss) for the period (VIII-IX)	(45.55)	(315.08)	98.96	(107.21)
XI	Other comprehensive Income				
	a). Items that will not be reclassified to profit or loss Re - measurement of the defined benefit obligations	1.56	8.02	(0.59)	6.24
	Less: Income tax	(0.39)	(2.02)	-	(1.57)
	b). Items that will be reclassified to profit or loss	-	-	0.17	-
	Less: Income tax	-	-	-	-
	Total Other comprehensive income (a+b)	1.17	6.00	(0.42)	4.67
XII	**Total comprehensive income for the period (X+XI)**	**(44.38)**	**(309.08)**	**98.54**	**(102.54)**
XIII	Paid-up equity share capital (Face value of ₹ 10/- per share)	6,103.06	6,103.06	6,103.06	6,103.06
XIV	Reserves i.e. Other equity				3,409.05
XV	Earnings/ (loss) per share (of ₹ 10/- each) (not annualised for quarter)				
	a) Basic	(0.07)	(0.52)	0.16	(0.18)
	b) Diluted	(0.07)	(0.52)	0.16	(0 18)

See accompanying notes to the unaudited financial results

G S K A & CO.
FRN 147093W
PUNE
Chartered Accountants

Notes:

1. The Statement of unaudited financial results for the quarter ended June 30, 2026, is drawn up in accordance with the Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which was reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 28, 2026. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion.

2. The above results have been prepared in accordance with the recognition and measurement requirements of Indian Accounting Standards ("Ind AS") notified under Companies (Indian Accounting Standards) Rules. 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

3. Majority of the matters relating to several financial and non-financial irregularities pertaining to period prior to November 12, 2011, were abated/settled. Accordingly, based on the steps taken by the Company and evidence available so far, the Company believes that the financial impact if any, with respect to those legacy matters, on the results of the Company is not material.

4. The Company's overseas subsidiaries namely Zenotech Farmaceutica Do Brasil Ltda (Zenotech-Brazil) and Zenotech Inc (Zenotech-USA) were defunct and reported as cancelled/revoked respectively based on the Registration Cancellation certificate dated 8th June 2022 and Long Form Standing certificate dated 15th June 2022 respectively, received from the concerned authorities.

   Winding up order for Zenòtech Laboratories Nigeria Limited has been received during FY: 2019-20. However, related filings with RBI are pending.

   Accordingly, the Company is of the view that it does not have subsidiaries, joint ventures and associates within the definition of Ind AS 110 and hence consolidated financial statements/Results are no longer applicable.

5. Other operating income relates to rentals for the Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities.

6. The Company has only one reportable segment, i.e. Pharmaceuticals.

7. The figures for the quarter ended 31st March, 2026 is the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year

8. Figures for previous period/ year have been regrouped to conform to the current period presentation.

By Order of the Board

Chairman of the Board meeting
DIN-01219312

Place: New Delhi
Date: July 28, 2026